Literature DB >> 8461221

Circulating endothelin in children with congenital heart disease.

I Adatia1, S G Haworth.   

Abstract

OBJECTIVE: To evaluate whether circulating endothelin, a peptide that is thought to play a part in mediating vascular tone, might be high in pulmonary hypertensive congenital heart disease.
DESIGN: A prospective study with a radioimmunoassay technique to estimate urinary and plasma endothelin concentrations.
SETTING: A supraregional referral centre for patients with congenital heart disease. PATIENTS: The 12 hour urinary endothelin concentration in young children with an increased pulmonary blood flow (n = 24, median age eight months) were compared with those in children with right ventricular outflow tract obstruction (n = 14, median age 1.5 years) and with those in healthy controls (n = 16, median age 1.8 years). The concentrations were also measured in adolescents with irreversible pulmonary vascular disease (n = 17, median age 18 years) and compared with those in controls of similar age (n = 19, median age 18.5 years). Also the plasma concentrations in the left atrium and pulmonary artery were measured in young children with either high (n = 11, median age 10.8 months) or low (n = 5, median age 1.0 year) pulmonary blood flow, in the peripheral arterial and venous blood of young children with either high (n = 13, median age 10.8 months) or low (n = 6 median age 1.9 years) pulmonary blood flow, and in the peripheral venous blood of seven healthy young children (median age 1.7 years).
RESULTS: The urinary excretion of endothelin was similar in young children of a similar age, whether they had high, low, or normal pulmonary blood flow. Also, urinary endothelin excretion in older patients with irreversible pulmonary vascular disease was similar to that in normal subjects of similar age. Urinary endothelin excretion in normal young children, however, was significantly greater than that in normal older subjects (p = 0.0001). There was no transpulmonary or arteriovenous difference detected in either children with high or low pulmonary blood flow, and plasma concentrations sampled from the left atrium, pulmonary artery, and systemic artery and vein were similar in both groups.
CONCLUSION: There was no evidence to implicate circulating endothelin in the pathogenesis of pulmonary vascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461221      PMCID: PMC1024986          DOI: 10.1136/hrt.69.3.233

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  14 in total

1.  Tissue specific distribution, clearance and vascular effects of endothelin in the pig.

Authors:  J Pernow; A Hemsén; J M Lundberg
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

2.  Plasma endothelin levels during surgery.

Authors:  Y Hirata; K Itoh; K Ando; M Endo; F Marumo
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy.

Authors:  M Rabinovitch; T Bothwell; B N Hayakawa; W G Williams; G A Trusler; R D Rowe; P M Olley; E Cutz
Journal:  Lab Invest       Date:  1986-12       Impact factor: 5.662

5.  Endothelin-1 from pulmonary artery and microvessels acts on vascular and airway smooth muscle.

Authors:  U S Ryan; M K Glassberg; K B Nolop
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

6.  Pressor effects of endothelin-1 and some analogs in the perfused superior mesenteric arterial bed of the rat.

Authors:  C R Hiley; S A Douglas; M D Randall
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

7.  Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodelling studied in lung biopsies.

Authors:  S M Hall; S G Haworth
Journal:  J Pathol       Date:  1992-02       Impact factor: 7.996

8.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

Authors:  G de Nucci; R Thomas; P D'Orleans-Juste; E Antunes; C Walder; T D Warner; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man.

Authors:  J Nowak; G A FitzGerald
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

10.  Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.

Authors:  L Roy; H R Knapp; R M Robertson; G A FitzGerald
Journal:  Circulation       Date:  1985-03       Impact factor: 29.690

View more
  5 in total

1.  An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.

Authors:  Reda Ibrahim; John T Granton; Sanjay Mehta
Journal:  Can Respir J       Date:  2006 Nov-Dec       Impact factor: 2.409

2.  Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.

Authors:  M D'Alto; C D Vizza; E Romeo; R Badagliacca; G Santoro; R Poscia; B Sarubbi; M Mancone; P Argiento; F Ferrante; M G Russo; F Fedele; R Calabrò
Journal:  Heart       Date:  2006-11-29       Impact factor: 5.994

3.  Effect of intracardiac repair on biosynthesis of thromboxane A2 and prostacyclin in children with a left to right shunt.

Authors:  I Adatia; S E Barrow; P D Stratton; J M Ritter; S G Haworth
Journal:  Br Heart J       Date:  1994-11

Review 4.  Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.

Authors:  Robert Tulloh
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

5.  Elevated level of plasma endothelin-1 in patients with atrial septal defect.

Authors:  Monika Komar; Jakub Podolec; Wojciech Płazak; Jakub Stępniewski; Bartosz Sobień; Lidia Tomkiewicz-Pająk; Tadeusz Przewłocki; Piotr Podolec
Journal:  Cardiovasc Ultrasound       Date:  2014-08-06       Impact factor: 2.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.